FDA targets compounded GLP‑1

The Food and Drug Administration has moved from tolerating many compounded GLP-1 weight-loss drugs to warning telehealth sellers and tightening the path for pharmacies to keep making them. (fda.gov) On March 3, 2026, the FDA said it sent 30 warning letters to telehealth companies over “false and misleading” claims about compounded GLP-1 products on their websites. The agency said some sites suggested the compounded drugs were safer, more effective, or equivalent to approved medicines without evidence. (fda.gov) The crackdown follows the end of the semaglutide shortage. The FDA said on February 21, 2025 that supply of semaglutide injections had stabilized, and its enforcement discretion for many state-licensed compounders ended after April 22, 2025. (fda.gov) Compounding is the pharmacy practice of mixing a custom drug for a specific patient, and federal law gives pharmacies more room to do that when an approved drug is in shortage. Once the shortage ends, pharmacies generally cannot keep making products that are “essentially a copy” of a commercially available drug in regular volume. (fda.gov) That shift hit the telehealth weight-loss market because many online sellers built fast-growing businesses around compounded semaglutide and tirzepatide during the shortages of Wegovy, Ozempic, Zepbound, and Mounjaro. The FDA said in February 2026 that it planned “decisive steps” to restrict GLP-1 active ingredients intended for use in non-approved compounded drugs that were being mass-marketed as alternatives to branded products. (fda.gov) The agency has also warned patients that unapproved GLP-1 drugs can carry dosing errors, quality problems, and risks tied to salt forms or added ingredients that differ from the approved medicines. FDA guidance specifically says a semaglutide product mixed with another active ingredient, such as vitamin B12, can still be treated as an impermissible copy in some circumstances. (fda.gov; fda.gov) Novo Nordisk, which makes Wegovy and Ozempic, added legal pressure in February 2026 by suing Hims & Hers over compounded semaglutide. On March 9, 2026, Novo said it would drop the case after Hims agreed to sell Novo’s branded drugs through its platform. (reuters.com; novonordisk-us.com) Hims said the same day that it was shifting its U.S. weight-loss business toward a broader mix of Food and Drug Administration-approved GLP-1 medicines, while keeping compounded semaglutide available only on a limited scale. Novo said the agreement reflected a “shift” in Hims’ U.S. business model. (investors.hims.com; novonordisk-us.com) For patients, the immediate question is continuity: whether a telehealth prescription will be filled with a branded drug, a narrowly tailored compounded one, or not at all. For telehealth companies and compounders, the next test is whether FDA warning letters turn into seizures, injunctions, or more deals that push the market back toward approved products. (pharmacytimes.com; fda.gov)